nach oben

Erschienen in:

12.05.2017 | Original Article

Effects of definitive and salvage radiotherapy on the distribution of lymphocyte subpopulations in prostate cancer patients

verfasst von: Eva K. Sage, Thomas E. Schmid, Hans Geinitz, Mathias Gehrmann, Michael Sedelmayr, Marciana N. Duma, Stephanie E. Combs, Gabriele Multhoff

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 8/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Radiotherapy (RT) is an established treatment for patients with primary and recurrent prostate cancer. Herein, the effects of definitive and salvage RT on the composition of lymphocyte subpopulations were investigated in patients with prostate cancer to study potential immune effects.

Patients and methods

A total of 33 prostate cancer patients were treated with definitive (n = 10) or salvage RT (n = 23) after biochemical relapse. The absolute number of lymphocytes and the distribution of lymphocyte subpopulations were analyzed by multiparameter flow cytometry before RT, at the end of RT, and in the follow-up period.

Results

Absolute lymphocyte counts decreased significantly after RT in both patient groups and a significant drop was observed in the percentage of B cells directly after RT from 10.1 ± 1.3 to 6.0 ± 0.7% in patients with definitive RT and from 9.2 ± 0.8 to 5.8 ± 0.7% in patients with salvage RT. In contrast, the percentages of T and natural killer (NK) cells remained unaltered directly after RT in both patient groups. However, 1 year after RT, the percentage of CD3⁺ T cells was significantly lower in patients with definitive and salvage RT. The percentage of regulatory T cells was slightly upregulated in primary prostate cancer patients after definitive RT, but not after salvage RT.

Conclusion

Definitive and salvage RT exert similar effects on the composition of lymphocyte subpopulations in prostate cancer patients. Total lymphocyte counts are lower in both patient groups compared to healthy controls and further decreased after RT. B cells are more sensitive to definitive and salvage RT than T and NK cells.

Nur mit Berechtigung zugänglich

Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66(1):7–30. doi:10.3322/caac.21332 CrossRefPubMed

Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49(6):1374–1403. doi:10.1016/j.ejca.2012.12.027 CrossRefPubMed

Pinkawa M, Piroth MD, Holy R, Djukic V, Klotz J, Krenkel B, Eble MJ (2011) Combination of dose escalation with technological advances (intensity-modulated and image-guided radiotherapy) is not associated with increased morbidity for patients with prostate cancer. Strahlenther Onkol 187(8):479–484. doi:10.1007/s00066-011-2249-z CrossRefPubMed

Catton C, Milosevic M (2003) Salvage radiotherapy following radical prostatectomy. World J Urol 21(4):243–252. doi:10.1007/s00345-003-0360-1 CrossRefPubMed

Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW, Walsh PC (2008) Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 299(23):2760–2769. doi:10.1001/jama.299.23.2760 CrossRefPubMedPubMedCentral

Pinkawa M (2015) Recent advances in definitive radiotherapy for prostate cancer. Eur Med J Oncol 3(1):41–48

Budach W, Sachkerer I (2014) Dose escalation: an update on randomised clinical trials. In: Geinitz R III (ed) Radiotherapy in prostate cancer. Medical radiology. Springer, Berlin, pp 89–93

Hou Z, Li G, Bai S (2015) High dose versus conventional dose in external beam radiotherapy of prostate cancer: a meta-analysis of long-term follow-up. J Cancer Res Clin Oncol 141(6):1063–1071. doi:10.1007/s00432-014-1813-1 CrossRefPubMed

Freedland SJ, Sutter ME, Dorey F, Aronson WJ (2003) Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 61(2):365–369CrossRefPubMed

10.

Geinitz H, Riegel MG, Thamm R, Astner ST, Lewerenz C, Zimmermann F, Molls M, Nieder C (2012) Outcome after conformal salvage radiotherapy in patients with rising prostate-specific antigen levels after radical prostatectomy. Int J Radiat Oncol Biol Phys 82(5):1930–1937. doi:10.1016/j.ijrobp.2011.03.003 CrossRefPubMed

11.

Jereczek-Fossa BA, Orecchia R (2007) Evidence-based radiation oncology: definitive, adjuvant and salvage radiotherapy for non-metastatic prostate cancer. Radiother Oncol 84(2):197–215. doi:10.1016/j.radonc.2007.04.013 CrossRefPubMed

12.

King CR (2012) The timing of salvage radiotherapy after radical prostatectomy: a systematic review. Int J Radiat Oncol Biol Phys 84(1):104–111. doi:10.1016/j.ijrobp.2011.10.069 CrossRefPubMed

13.

Izawa JI (2009) Salvage radiotherapy after radical prostatectomy. Can Urol Assoc J 3(3):245–250PubMedPubMedCentral

14.

Malone S, Croke J, Roustan-Delatour N, Belanger E, Avruch L, Malone C, Morash C, Kayser C, Underhill K, Li Y, Malone K, Nyiri B, Spaans J (2012) Postoperative radiotherapy for prostate cancer: a comparison of four consensus guidelines and dosimetric evaluation of 3D-CRT versus tomotherapy IMRT. Int J Radiat Oncol Biol Phys 84(3):725–732. doi:10.1016/j.ijrobp.2011.12.081 CrossRefPubMed

15.

Schaue D, Xie MW, Ratikan JA, McBride WH (2012) Regulatory T cells in radiotherapeutic responses. Front Oncol 2:90. doi:10.3389/fonc.2012.00090 PubMedPubMedCentral

16.

Demaria S, Golden EB, Formenti SC (2015) Role of local radiation therapy in cancer immunotherapy. JAMA Oncol 1(9):1325–1332. doi:10.1001/jamaoncol.2015.2756 CrossRefPubMed

17.

Bos PD, Plitas G, Rudra D, Lee SY, Rudensky AY (2013) Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy. J Exp Med 210(11):2435–2466. doi:10.1084/jem.20130762 CrossRefPubMedPubMedCentral

18.

Spiotto M, Fu YX, Weichselbaum RR (2016) The intersection of radiotherapy and immunotherapy: mechanisms and clinical implications. Sci Immunol 1(3). doi:10.1126/sciimmunol.aag1266 PubMedPubMedCentral

19.

Formenti SC, Demaria S (2009) Systemic effects of local radiotherapy. Lancet Oncol 10(7):718–726. doi:10.1016/s1470-2045(09)70082-8 CrossRefPubMedPubMedCentral

20.

Sage EK, Schmid TE, Sedelmayr M, Gehrmann M, Geinitz H, Duma MN, Combs SE, Multhoff G (2016) Comparative analysis of the effects of radiotherapy versus radiotherapy after adjuvant chemotherapy on the composition of lymphocyte subpopulations in breast cancer patients. Radiother Oncol 118(1):176–180. doi:10.1016/j.radonc.2015.11.016 CrossRefPubMed

21.

Deloch L, Derer A, Hartmann J, Frey B, Fietkau R, Gaipl US (2016) Modern radiotherapy concepts and the impact of radiation on immune activation. Front Oncol 6:141. doi:10.3389/fonc.2016.00141 CrossRefPubMedPubMedCentral

22.

Multhoff G, Gaipl US, Niedermann G (2012) The role of radiotherapy in the induction of antitumor immune responses. Strahlenther Onkol 188(Suppl 3):312–315. doi:10.1007/s00066-012-0206-0 CrossRefPubMed

23.

Frey B, Rubner Y, Wunderlich R, Weiss EM, Pockley AG, Fietkau R, Gaipl US (2012) Induction of abscopal anti-tumor immunity and immunogenic tumor cell death by ionizing irradiation – implications for cancer therapies. Curr Med Chem 19(12):1751–1764CrossRefPubMed

24.

Cihan YB, Arslan A, Ergul MA (2013) Subtypes of white blood cells in patients with prostate cancer or benign prostatic hyperplasia and healthy individuals. Asian Pac J Cancer Prev 14(8):4779–4783CrossRefPubMed

25.

Pinkawa M, Ribbing C, Djukic V, Klotz J, Holy R, Eble MJ (2015) Early hematologic changes during prostate cancer radiotherapy predictive for late urinary and bowel toxicity. Strahlenther Onkol 191(10):771–777. doi:10.1007/s00066-015-0841-3 CrossRefPubMed

26.

Gershkevitsh E, Rosenberg I, Dearnaley DP, Trott KR (1999) Bone marrow doses and leukaemia risk in radiotherapy of prostate cancer. Radiother Oncol 53(3):189–197CrossRefPubMed

27.

Stöver I, Feyer P (2010) Praxismanual Strahlentherapie. Springer, Berlin, p 31CrossRef

28.

Chapel H, Haeney M, Misbah S, Snowden N (2014) Essentials of clinical immunology, 6th edn. Wiley-Blackwell, Chichester

29.

Multhoff G, Meier T, Botzler C, Wiesnet M, Allenbacher A, Wilmanns W, Issels RD (1995) Differential effects of ifosfamide on the capacity of cytotoxic T lymphocytes and natural killer cells to lyse their target cells correlate with intracellular glutathione levels. Blood 85(8):2124–2131PubMed

30.

Belka C, Ottinger H, Kreuzfelder E, Weinmann M, Lindemann M, Lepple-Wienhues A, Budach W, Grosse-Wilde H, Bamberg M (1999) Impact of localized radiotherapy on blood immune cells counts and function in humans. Radiother Oncol 50(2):199–204CrossRefPubMed

31.

Sotosek S, Sotosek Tokmadzic V, Mrakovcic-Sutic I, Tomas MI, Dominovic M, Tulic V, Sutic I, Maricic A, Sokolic J, Sustic A (2011) Comparative study of frequency of different lymphocytes subpopulation in peripheral blood of patients with prostate cancer and benign prostatic hyperplasia. Wien Klin Wochenschr 123(23–24):718–725. doi:10.1007/s00508-011-0096-7 CrossRefPubMed

32.

Nardone V, Botta C, Caraglia M, Martino EC, Ambrosio MR, Carfagno T, Tini P, Semeraro L, Misso G, Grimaldi A, Boccellino M, Facchini G, Berretta M, Vischi G, Rocca BJ, Barone A, Tassone P, Tagliaferri P, Del Vecchio MT, Pirtoli L, Correale P (2016) Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse. Cancer Biol Ther. doi:10.1080/15384047.2016.1235666 PubMed

33.

Ness N, Andersen S, Valkov A, Nordby Y, Donnem T, Al-Saad S, Busund LT, Bremnes RM, Richardsen E (2014) Infiltration of CD8+ lymphocytes is an independent prognostic factor of biochemical failure-free survival in prostate cancer. Prostate 74(14):1452–1461. doi:10.1002/pros.22862 CrossRefPubMed

34.

Tao CJ, Chen YY, Jiang F, Feng XL, Jin QF, Jin T, Piao YF, Chen XZ (2016) A prognostic model combining CD4/CD8 ratio and N stage predicts the risk of distant metastasis for patients with nasopharyngeal carcinoma treated by intensity modulated radiotherapy. Oncotarget 7(29):46653–46661. doi:10.18632/oncotarget.9695 PubMedPubMedCentral

35.

Ordonez R, Henriquez-Hernandez LA, Federico M, Valenciano A, Pinar B, Lloret M, Bordon E, Rodriguez-Gallego C, Lara PC (2014) Radio-induced apoptosis of peripheral blood CD8 T lymphocytes is a novel prognostic factor for survival in cervical carcinoma patients. Strahlenther Onkol 190(2):210–216. doi:10.1007/s00066-013-0488-x CrossRefPubMed

36.

McClatchey KD (2002) Clinical laboratory medicine, 2nd edn. Lippincott Wiliams & Wilkins, Philadelphia

Titel: Effects of definitive and salvage radiotherapy on the distribution of lymphocyte subpopulations in prostate cancer patients
verfasst von: Eva K. Sage
Thomas E. Schmid
Hans Geinitz
Mathias Gehrmann
Michael Sedelmayr
Marciana N. Duma
Stephanie E. Combs
Gabriele Multhoff
Publikationsdatum: 12.05.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 8/2017
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-017-1144-7

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Effects of definitive and salvage radiotherapy on the distribution of lymphocyte subpopulations in prostate cancer patients

Abstract

Background

Patients and methods

Results

Conclusion

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Background

Patients and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2017

Quality assurance of the PREOPANC trial (2012-003181-40) for preoperative radiochemotherapy in pancreatic cancer

30-Tage-Letalität nach systemischer Chemotherapie

Erratum to: Combined p16 and p53 expression in cervical cancer of unknown primary and other prognostic parameters

Successful treatment of a rare case of ameloblastic fibrosarcoma with radiation therapy

Improved oncologic outcome with chemoradiotherapy followed by surgery in unresectable intrahepatic cholangiocarcinoma

Radioablation of adrenal gland malignomas with interstitial high-dose-rate brachytherapy

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie